PYCR1 inhibition reduces myeloma cell proliferation and survival by triggering unfolded protein response pathway in vitro and in vivo to increase the efficacy of bortezomib[44] (Fig. 4). This evidence concerns the gene PYCR1 and plasma cell myeloma.